Sign in
Taking people in United StatesNo phase

A Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery

Key facts

Who runs it
Cleveland Eye Clinic
Where
Brecksville and Largo, United StatesSee the 2 sites
Trial code
Status
Recruiting
People taking part
36 people, planned
Started
22 Sept 2026
Expected to end
Dec 2026
Type of study
Observational
Treatments tested
  • Manual expression of meibomian glands after thermal eyelid therapy
Record updated
10 November 2026

Who can take part

Age
50 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (26)Hide the full registry criteria

Who can take part

  • Age 50-75 years
  • Diagnosis of MGD and DED
  • OSDI score 23-79
  • TBUT > 1 second and ≤ 7 seconds
  • MGSS <12 in both eyes
  • ≥15 expressible meibomian glands
  • Candidate for cataract surgery planning (ie. Phakic)

Who cannot take part

  • Any of the following dry eye treatments:; OAice-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation [LipiFlow], iLuxetc.) within 12 months prior to Screening either as part of routine care or clinical investigation; Planned or recent surgical procedures to the eye or eyelid (90 days prior to Screening); Meibomian gland expression within 6 months prior to Screening; Blephex or debridement within 3 months prior TC-2026-TearCare, V2, 15JUN2026 Page 10 of 26 to Screening; Punctal occlusion (including collagen, e.g. Soft Plug, UltraPlug, or crosslinked hyaluronic acid, e.g. Lacrifill) or punctal plugs within 15 days of the Screening visit; Use of tear neurostimulators (i.e., True Tear, iTear100, Tyrvaya) within 2 weeks of the baseline visit. (Subjects must refrain from using tear neurostimulators for the duration of the study); Any history of meibomian gland probing
  • History of eyelid, conjunctiva, or corneal surgery (including refractive surgery) within 12 months prior to Screening
  • Contact lens use within 2 weeks of the Procedure visit. Subjects presenting at the Screening visit using contact lenses must agree to discontinue use for a full 2 weeks (14 days) prior to the Procedure Visit
  • Recurrent clinically significant eye inflammation, other than dry eye, within 3 months prior to screening based on Investigator's judgement
  • Any active, clinically significant allergic, vernal, or giant papillary conjunctivitis. 16. Ocular trauma within 3 months prior to Screening
  • Known history of diminished or abnormal facial, periocular, ocular or corneal sensation 18. Systemic diseases, in the Investigator's medical judgement, resulting in dry eye (e.g. autoimmune diseases such as Sjogren's syndrome, rheumatoid arthritis, lupus, Graves' disease, sarcoidosis, etc.) 19. Subject is currently using Retin A /Retin A derivatives. 20. Subject has permanent eyeliner/lid tattoos, eyelash extensions or wears false eyelashes
  • Any history of chalazion surgery, surgery on the tarsal conjunctiva, radial keratotomy (RK), complicated blepharoplasty, lid reconstruction, or significant complications post-refractive surgery
  • History of Herpes Simplex or Herpes Zoster of the eye or eyelid
  • Any active, clinically significant ocular or peri-ocular infection, inflammation, or irritation based on Investigator's judgement
  • Clinically significant dermatologic or cutaneous disease of the eyelid or periocular area based on Investigator's judgement
  • Corneal surface abnormalities such as corneal epithelial defects (other than punctate staining), ulcers, corneal epithelial dystrophies, keratoconus, and ectatic disease of the cornea
  • Allergies to silicone tissue adhesives, acrylates and/or copper. 24. Subject has a pacemaker or implantable cardiac defibrillators (ICD). 25. Co-existing condition, either ocular or non-ocular that, in the judgement of the Investigator could aAect the safety or eAectiveness of treatment or the compliance of the subject to the protocol; -
  • Use of:; Cyclosporine, Xiidra, or serum tears within 30 days prior to Screening; Antihistamines (oral or topical) within 7 days prior to Screening; Oral tetracyclines or azithromycin within 30 days prior to Screening; Topical ophthalmic antibiotics, anti-glaucoma medications, steroids, nonsteroidal anti-inflammatory medications within 30 days prior to Screening; Isotretinoin (e.g. Accutane) at any time
  • Subject is currently using Latisse, Lash Boost or any other type of eyelash growth serum. Prostaglandin analog products such as Latisse should not be used within 30 days of the Screening visit
  • Active hordeolum, stye, or chalazion at the time of the Screening visit
  • Clinically significant anterior blepharitis. In addition, collarettes or flakes of more than one quarter of the eyelid are excluded
  • Clinically significant eyelid abnormalities in either eye (e.g. entropion/ectropion, blepharospasm, aponeurotic ptosis, lagophthalmos, distichiasis, trichiasis)
  • In the clinical judgement of the Investigator, meibomian glands have significant capping, atrophy, or are unable to be expressed, digitally or with a cotton swab. TC-2026-TearCare, V2, 15JUN2026 Page 11 of 26
  • Temporary false eyelashes, lash extensions, or any other type of false eyelash within 15 days of the Screening Visit

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Dry eye syndrome or meibomian gland dysfunction

This trial is currently available in United States.

  • Cleveland Eye ClinicBrecksville, United StatesContact: Erin Kus-KreidlerTaking people
  • The Eye Institute of West FloridaLargo, United StatesContact: Renee BondurantNot yet recruiting

About the trial

What the trial wants to find out

The goal of this study is to evaluate whether TearCare treatment stabilizes corneal measurements sufficiently to determine when cataract biometry can be considered reliable.

The group in the trial

  • Subjects with Dry Eye Syndrome, Meibomian Gland Dysfunction and Cataracts

    Patients who would likely benefit from having TearCare done before having cataract surgery.

    Treatment: Manual expression of meibomian glands after thermal eyelid therapy

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi Center, Peri-Cataract Evaluation of TearCare With Expression on Ocular Biometry and Surgical Measurements
Criteria questions
Built from NCT07928986, who can take part
Record updated
10 November 2026